Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Against Gadolinium Use In MRIs For Kidney Failure Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Contrast agent should be used in such patients only if “clearly necessary,” FDA says.

You may also be interested in...



FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease

However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.

FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease

However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.

Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee

Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.

Topics

UsernamePublicRestriction

Register

PS064472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel